These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21479696)

  • 1. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
    Gharwan H; Truica CI
    Med Oncol; 2012 Jun; 29(2):1197-201. PubMed ID: 21479696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
    Hada R; Poudyal B; Sharma A; Khatri R
    JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
    Jimenez-Zepeda VH; Vajpeyi R; John R; Trudel S
    Int J Hematol; 2012 Jul; 96(1):125-31. PubMed ID: 22573235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
    Minarik J; Scudla V; Tichy T; Pika T; Bacovsky J; Lochman P; Zadrazil J
    Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.
    Wu CK; Yang AH; Lai HC; Lin BS
    BMC Nephrol; 2017 May; 18(1):170. PubMed ID: 28545410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Improved prognosis in light chain nephropathy due to multiple myeloma].
    Juul JS; Larsen T; Marcussen N; Pedersen EB
    Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
    Talbot B; Wright D; Basnayake K
    BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25326567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Complete remission achieved in a multiple myeloma patient with elevated serum KL-6 level by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone].
    Okuno Y; Nishimura N; Nosaka K; Hata H; Mitsuya H
    Rinsho Ketsueki; 2014 Apr; 55(4):461-5. PubMed ID: 24850459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful renal recovery from multiple myeloma-associated crystalline light chain cast nephropathy and accompanying acute kidney injury with early use of bortezomib-based therapy: a case report and literature review.
    Miki K; Shimamura Y; Maeda T; Moniwa N; Ogawa Y; Shimizu T; Hayashi T; Sakai H; Takizawa H
    CEN Case Rep; 2023 Feb; 12(1):56-62. PubMed ID: 35854043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chain disease)--a case report.
    Rabrenović V; Mijušković Z; Marjanović S; Rabrenović M; Jovanović D; Antić S; Ignjatović L; Petrović M; Pilcević D
    Vojnosanit Pregl; 2015 Feb; 72(2):196-9. PubMed ID: 25831916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Bianchi G; Richardson PG; Anderson KC
    J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
    Kumar V; Elkins S; Gaston RS; Prendergast MB; Reddy V; Cook WJ; Sanders PW
    Clin Transpl; 2009; ():439-41. PubMed ID: 20524312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Grannis CH; Dewan VN; Wang RC
    Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.